Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-650-8 | CAS number: 123-77-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Basic toxicokinetics
The metabolism studies indicate that Azodicarbonamide was absorbed, metabolised and excreted in rats. The acute rat oral, dermal and inhalation studies, together with the repeat dose inhalation study, indicated that despite the absorption, metabolism and excretion of Azodicarbonamide there was no resultant adverse toxicity. Similarly, there was no evidence of skin or eye irritation in rabbits or sensitization potential in Guinea pigs.
Dermal absorption
No data available. No data required.
Discussion on bioaccumulation potential result:
No information is available on the toxicokinetics of azodicarbonamide in humans. Most of the toxicokinetic data available for azodicarbonamide come from animal studies (CICAD 1999- SIAR 2001).
Absorption
Absorption of azodicarbonamide has been demonstrated following both a single inhalation exposure of up to 6 h (ca. 34% of dose) and a single oral administration (10–33% of dose) of radiolabelled azodicarbonamide to rats F344. In contrast, approximately 90% of a single intratracheally instilled dose was apparently absorbed. The difference in absorption between inhaled and intratracheally instilled azodicarbonamide could be related to the fact that much of the inhaled azodicarbonamide did not reach the lower respiratory tract. Half an hour after a 6-h nose-only exposure of rats to 25 mg/m3 of a dry aerosol (average mass aerodynamic diameter 3.4 µm), 78% of the calculated total intake was located in the gastrointestinal tract (Mewhinney et al., 1987).
Distribution
No data.
Metabolism
Azodicarbonamide is readily converted to biurea (1,2-Hydrazinedicarboxamide, CAS 110-21-4), the only breakdown product identified, and it is likely that systemic exposure is principally to this derivative rather than to the parent compound (Mewhinney et al., 1987). Azodicarbonamide readily undergoes reduction in the presence of thiol groups to form the stable compound biurea. Given that thiol groups are also present in many biological molecules, there is the potential for this reaction to take place wherever azodicarbonamide encounters thiol groups in biological systems. This has been demonstrated in an experiment in which radiolabelled azodicarbonamide was added to fresh rat blood (Mewhinney et al., 1987). All radioactivity was in the form of biurea within 5 min when untreated blood was used. Radioactivity associated with azodicarbonamide was detected only in blood to which 5 mg unlabelled azodicarbonamide/ml blood was added. This level is very much greater than the levels that humans are likely to encounter.
This metabolism is confirmed by an other study: after repeated inhalation of ADCA for 13weeks in rats no ADCA was found in kidney or lungs or bronchi, but biurea was found in lungs and bronchi (Medinsky et al., 1990)
Excretion
Following exposure by both inhalation and oral routes, substantial quantities of the substance remain unabsorbed from the gastrointestinal tract and are passed out in the faeces. Elimination of absorbed azodicarbonamide/biurea is rapid, occurring predominantly via the urine (99% within 72h), and there is very little systemic retention of biurea (Mewhinney et al., 1987).
After oral administration of suspension of radiolabelled azodicarbonamide in water or corn oil, less than 10% of the ADA:water or ADA:corn oil dose was excreted in urine, with virtually all of the dose being excreted in faeces by 24h after administration (IRDC 1982, cited in Mewhinney et al., 1987).
Conclusion
The previous metabolism studies indicate that Azodicarbonamide was absorbed, metabolised and excreted in rats. The acute rat oral, dermal and inhalation studies, together with the repeat dose inhalation study, indicated that despite the absorption, metabolism and excretion of Azodicarbonamide there was no resultant adverse toxicity. Similarly, there was no evidence of skin or eye irritation in rabbits or sensitization potential in Guinea pigs.
References
Mewhinney J.A., Ayres P.H., Bechtold W.E. et al. 1987. The fate of inhaled azodicarbonamide in rats. Fundam Appl Toxicol; 8 (3). 372-381.
International research and Development Corporation (IRDC), biological disposition of orally administered azodicarbonamide in male rats, unpublished report to the National Toxicology Program, Report No. 5702-125, 1982.
Medinsky et al., (1990) Effect of inhaled azodicarbonamide on F344/N rats and B6C3F1 mice with 2-week and 13-week inhalation exposures Fundamental and Applied Toxicology 15, pages 308-319.
OECD SIDS Initial assessment report for SIAM 12, 2001. Azodicarbonamide.WHO IPCS,
Concise International Chemical Assessment Document (CICAD) 16. 1999. Azodicarbonamide.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.